Clinical Trials | April 22, 2026
Ultomiris shows strong interim results in Phase III IgA nephropathy trial
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
Medical experts point to a growing body of research linking energy drinks to liver injury
The innovation is particularly suited for bone and cartilage repair
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The collaboration combines Takara Bio’s large-scale testing technology with Resistomap’s data-driven AMR intelligence
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Former Wavemaker executive to lead media strategy and digital transformation agenda
The new unit is expected to serve thousands of patients annually, helping address a critical gap in dialysis access
The license is valid for five years, effective from April 9, 2026
Subscribe To Our Newsletter & Stay Updated
